Treatment Resistant Depression Market, By Drug Type (Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Others, Atypical agents, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jun 2024

Code : CMI5196

Pages :197

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Treatment Resistant Depression Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

New drug approval and launch

Key players in the market are actively pursuing approvals for their innovative drugs designed to treat treatment resistant depression and subsequently launching them in the market. These efforts are anticipated to significantly contribute to market growth in the coming years. For instance, Denovo Biopharma LLC, a clinical-stage biopharmaceutical company specializing in biomarker-driven precision medicines, received authorization from the U.S. Food and Drug Administration (FDA) in January 2022 for its investigational new drug (IND) application of DB104 (liafensine) for treatment resistant depression (TRD). This milestone allows Denovo to initiate a global Phase 2b clinical trial to evaluate the safety and effectiveness of liafensine in TRD patients.

Key Players Insights